Literature DB >> 3277611

Apolipoprotein E polymorphism and atherosclerosis.

J Davignon1, R E Gregg, C F Sing.   

Abstract

The apo E locus contributes to determining the variation in plasma cholesterol levels of healthy and diseased populations. It also influences the expression of hyperlipidemia and appears to modulate the susceptibility to atherosclerosis in a complex multifactorial interaction. There is evidence that the presence of apo E2 is protective, whereas that of apo E4 predisposes to coronary artery disease. The burden of proof, however, lies on future, well-designed clinical trials and prospective studies. The study of the biological significance of the apo E polymorphism in humans has emphasized the importance of gene-gene and gene-environment interactions in the pathogenesis of hyperlipidemia and atherosclerosis. The apo E polymorphism involves the coding region of the apo E gene and results in alterations of the gene product which, in turn, either directly or secondarily affect the metabolic fate of the lipoprotein particles. Rapid advances in knowledge over the last decade have provided a metabolic explanation for the observation of the opposite effects of the epsilon 4 and the epsilon 2 alleles on lipoprotein levels. Apo E2 has lower receptor binding affinity which results in delayed clearance of apo E2-bearing lipoprotein particles from plasma. Apo E4 is distributed differently from apo E3 between VLDL and HDL, is degraded more rapidly than apo E3, and may enhance the catabolism of E4-bearing particles, leading to other alterations in lipoprotein metabolism which result in elevated levels of LDL. In view of the significant opposite impacts of the epsilon 4 and the epsilon 2 alleles on plasma LDL cholesterol concentrations, it is evident that determination of the apo E phenotype will become a useful adjunct to the assessment of the cardiovascular risk profile of an individual. In addition, the relationship between the epsilon 2 allele and type III hyperlipoproteinemia provides a valuable model for the study of complex genetic interactions in the pathogenesis of hyperlipidemia. The further study of apo E and its interactions shows great promise for a deeper comprehension of the pathogenesis of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3277611     DOI: 10.1161/01.atv.8.1.1

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  306 in total

1.  The effects of genotype and infant weight on adult plasma levels of fibrinogen, factor VII, and LDL cholesterol are additive.

Authors:  J A Henry; M Bolla; C Osmond; C Fall; D J Barker; S E Humphries
Journal:  J Med Genet       Date:  1997-07       Impact factor: 6.318

2.  Hypercholesterolemia and Dyslipidemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

3.  Detection of single base differences using biotinylated nucleotides with very long linker arms.

Authors:  K J Livak; F W Hobbs; R J Zagursky
Journal:  Nucleic Acids Res       Date:  1992-09-25       Impact factor: 16.971

Review 4.  The Gordon Wilson Lecture. Plasma cholesterol: atherogenesis and mortality.

Authors:  W R Fisher
Journal:  Trans Am Clin Climatol Assoc       Date:  1993

5.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 6.  Emerging clinical applications in cardiovascular pharmacogenomics.

Authors:  Samir B Damani; Eric J Topol
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-08-20

Review 7.  Indications for lipid-lowering drugs.

Authors:  J Davignon
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Contributions of 18 additional DNA sequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism.

Authors:  Jari H Stengård; Andrew G Clark; Kenneth M Weiss; Sharon Kardia; Deborah A Nickerson; Veikko Salomaa; Christian Ehnholm; Eric Boerwinkle; Charles F Sing
Journal:  Am J Hum Genet       Date:  2002-08-05       Impact factor: 11.025

9.  Apolipoprotein E polymorphism and clinical course in childhood nephrotic syndrome.

Authors:  Sung-Do Kim; Il-Soo Kim; Byung-Cheol Lee; Kang-Duk Choi; Joo-Ho Chung; Chun-Gyoo Ihm; Byoung-Soo Cho
Journal:  Pediatr Nephrol       Date:  2003-02-13       Impact factor: 3.714

10.  Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia.

Authors:  J Kawamata; S Tanaka; S Shimohama; K Ueda; J Kimura
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.